Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome

被引:44
作者
Der, H.
Kerekes, G.
Veres, K.
Szodoray, P.
Toth, J.
Lakos, G.
Szegedi, G.
Soltesz, P.
机构
[1] Univ Debrecen, Med & Hlth Sci Ctr, Inst Internal Med, Dept Med 3, H-4004 Debrecen, Hungary
[2] Univ Debrecen, Med & Hlth Sci Ctr, Clin Res Ctr, Debrecen, Hungary
[3] Univ Debrecen, Med & Hlth Sci Ctr, Clin Immunopathol Lab, Dept Med 3, Debrecen, Hungary
[4] Hungarian Acad Sci, Autoimmune Res Grp, H-1051 Budapest, Hungary
[5] Univ Debrecen, Autoimmune Res Grp, Debrecen, Hungary
关键词
endothelium-dependent vasodilation; primary antiphospholipid syndrome; von Willebrand factor;
D O I
10.1177/0961203307080224
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Primary antiphospholipid syndrome (APS) is characterized by venous or arterial thrombotic events and/or recurrent abortions, fetal death, preeclasmpsia, eclampsia in the presence of anticardiolipin antibodies or lupus anticoagulant, in the absence of accompanying diseases. Anti phospholipid antibodies can activate endothelial cells, and were recently implicated in atherosclerosis. To assess potential endothelial impairment and early signs of atherosclerosis, flow-mediated (endothelium-dependent) and nitrate-mediated (endothelium independent) vasodilation, as well as von Willebrand factor antigen level and carotid artery intima-media thickness (IMT) were measured in patients with primary antiphospholipid syndrome and in healthy controls. Flow-mediated vasodilation in patients with primary APS was significantly lower than that of controls (3.43 +/- 2.86% versus 7.96 +/- 3.57%; P < 0.0001). We also found significantly higher von Willebrand antigen levels in patients with primary APS than in the control group (157.91 +/- 52.45% versus 125.87 +/- 32.8%; P = 0.012). Moreover, carotid artery IMT was significantly larger in the primary APS group compared to controls (0.714 +/- 0.2 mm versus 0.58 0.085 mm; P = 0.0037). Out- results reflect ongoing endothelial damage and accelerated atherosclerosis in patients with primary APS, and suggest that vasoprotective therapy may be beneficial in the treatment of these patients.
引用
收藏
页码:497 / 503
页数:7
相关论文
共 42 条
[31]   Cardiac involvement in systemic autoimmune diseases [J].
Riboldi, P ;
Gerosa, M ;
Luzzana, C ;
Catelli, L .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2002, 23 (03) :247-261
[32]   Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus [J].
Roman, MJ ;
Shanker, B ;
Davis, A ;
Lockshin, MD ;
Sammaritano, L ;
Simantov, R ;
Crow, MK ;
Schwartz, JE ;
Paget, SA ;
Devereux, RB ;
Salmon, JE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (25) :2399-2406
[33]  
Schächinger V, 2000, Z KARDIOL, V89, P70
[34]  
SHERER Y, 2001, CURR ATHEROSCLER REP, V4, P328
[35]   Atherosclerosis and the antiphospholipid syndrome: A link unravelled? [J].
Shoenfeld, Y ;
Harats, D ;
George, J .
LUPUS, 1998, 7 :S140-S143
[36]   Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? [J].
Shoenfeld, Y ;
Wu, RH ;
Dearing, LD ;
Matsuura, E .
CIRCULATION, 2004, 110 (17) :2552-2558
[37]  
SORENSEN KE, 1995, BRIT HEART J, V74, P247
[38]   HEMOSTATIC FACTORS AND THE RISK OF MYOCARDIAL-INFARCTION OR SUDDEN-DEATH IN PATIENTS WITH ANGINA-PECTORIS [J].
THOMPSON, SG ;
KIENAST, J ;
PYKE, SDM ;
HAVERKATE, F ;
VANDELOO, JCW .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (10) :635-641
[39]  
Tikiz C, 2005, J RHEUMATOL, V32, P2095
[40]   Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study [J].
Vlachoyiannopoulos, PG ;
Kanellopoulos, PG ;
Ioannidis, JPA ;
Tektonidou, MG ;
Mastorakou, I ;
Moutsopoulos, HM .
RHEUMATOLOGY, 2003, 42 (05) :645-651